PSYRX

The world urgently needs a new way to treat mental health conditions, and at Psyrx we are developing a combination of an approved drug from the SSRI family with a low dosage of ibogaine. Meant to improve anti-depressant treatment, with a convenient daily dose - the treatment does not cause a psychedelic effect and is non-disruptive to people's way of life. It also decreases the side effects of current medications - aimed at transforming and optimizing mental health treatment outcomes... At Psyrx we believe psychedelics are a big part of the solution for the global mental health crisis. Bringing over 20 years of experience in the pharmaceutical, medical device and cannabis industries, we set out to transform the growing psychedelic drug discovery market. Psyrx is one of the few companies to offer GMP-approved, API of Psilocybin and Ibogaine... Natural Pharmaceutical Grade Psychedelics for a New Generation of Mental Health Therapeutics